Antithrombotic Drug Use in Patients With Ischemic Stroke and Microbleeds

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05032053

Acronym

AIM-2

Enrollment

3000

Registered

2021-09-02

Start date

2022-03-01

Completion date

2027-12-01

Last updated

2026-07-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic Stroke

Keywords

Ischemic Stroke, microbleeds, Proteomics, antithrombotic drug

Brief summary

To observe the effect of different antithrombotic drugs on the prognosis of ischemic stroke patients with cerebral microbleeds. And further combined with proteomic methods to explore serological markers that can be used to accurately predict the prognosis of such patients.

Detailed description

Cerebral microbleeds (CMBs) are caused by microvascular lesions in the brain, which is a subclinical deposition of hemosiderin after the damage of microvascular. Antithrombotic drug are widely used in the secondary prevention of patients with ischemic stroke. Studies have shown that antithrombotic drug can increase the incidence of intracranial hemorrhage in ischemic stroke patients with cerebral microbleeds. For such patients, how to carry out effective and safe antithrombotic therapy is still unclear. We will study from two aspects: 1) We designed a cohort registration study to observe the prognosis and progress of CMBs in ischemic stroke patients one year after using various antithrombotic drugs. 2) Data independent acquisition quantitative proteomics (DIA quantitative proteomics) will be used to screen serum protein markers that may affect the prognosis of ischemic stroke patients with CMBs.

Interventions

DRUGAntithrombotic drugs

The purpose of our study is to observe the effect of various antithrombotic drugs on the prognosis of ischemic stroke patients with cerebral microbleeds.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

40 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Patients diagnosed clinically as ischemic stroke; 2. Age ≥ 40 years; 3. Onset time ≤ 3 months; 4. Informed consent was signed.

Exclusion criteria

1. Patients with symptomatic intracranial hemorrhage; 2. bleeding lesion \> 10 mm was found on SWI; 3. Vascular malformations, tumors, abscesses or other major non ischemic brain diseases were present; 4. There are contraindications for antithrombotic drugs use; 5. Serious systemic diseases; 6. Refusal to sign informed consent or poor compliance.

Design outcomes

Primary

Measure	Time frame	Description
Increase of cerebral microbleeds	1 year after onset	How many cerebral microbleeds increased after 1 year of antithrombotic drugs treatment. The number of microbleeds will be detected by MR-SWI.

Secondary

Measure	Time frame	Description
Stroke recurrence rate	1 year after onset	recurrence rate of ischemic stroke
The incidence of cerebral hemorrhage	1 year after onset	—

Countries

China

Contacts

CONTACTWen Jiang, Ph.D

jiangwen@fmmu.edu.cn86-029-84771319

CONTACTFang Yang, Ph.D

fyangx@fmmu.edu.cn86-029-84771319

STUDY_DIRECTORWen Jiang, Ph.D

Department of Neurology, Xijing Hospital, Fourth Military Medical University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 31, 2026